Novavax NVAX Right-of-use asset, net
Right-of-use asset, net at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept nvax:LeaseRightOfUseAsset.
The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Novavax's right-of-use asset, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Novavax's right-of-use asset, net?
- Novavax (NVAX) reported right-of-use asset, net of $21.36M in Q1 2026.
- How has Novavax's right-of-use asset, net changed year-over-year?
- Novavax's right-of-use asset, net decreased by 86.4% year-over-year, from $157.5M to $21.36M.
- What is the long-term trend for Novavax's right-of-use asset, net?
- Over 4 years (2021 to 2025), Novavax's right-of-use asset, net has grown at a -13.1% compound annual growth rate (CAGR), from $40.12M to $22.9M.
- What does right-of-use asset, net mean?
- This represents the capitalized value of the right to use an underlying asset, such as office space or laboratory facilities, over the term of a lease agreement. It reflects the company's long-term commitment to leased infrastructure necessary for research, development, and administrative operations. Monitoring this balance helps investors assess the scale of the company's leased footprint and its long-term fixed operating obligations.